{"id":"W4379336690","doi":"10.1200/jco.2023.41.16_suppl.4596","title":"A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Bladder cancer; Cystectomy; Urology; Tolerability; Internal medicine; Interim analysis; Oncology; Adverse effect; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001937212,0.001890358,0.00141701,0.000401039,0.0005221646,0.001398987,0.001016629,0.002080955,0.005784372],"category_scores_gemma":[0.001216329,0.0007028493,0.001296543,0.0003395053,0.001019741,0.001299884,0.0004841916,0.004011692,0.001177371],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001255871,"about_ca_system_score_gemma":0.001363759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009985246,"about_ca_topic_score_gemma":0.00251927,"domain_scores_codex":[0.9994438,0.0002914668,0.00002078845,0.0000775001,0.00003185725,0.0001346418],"domain_scores_gemma":[0.9991217,0.0001698644,0.0001608255,0.00008813626,0.00004662895,0.0004128743],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7288074,0.1234312,0.004627095,0.0009141879,0.00121314,0.0003056037,0.0004053517,0.002252979,0.02982939,0.0004154274,0.00592885,0.1018694],"study_design_scores_gemma":[0.4942595,0.4910463,0.005841847,0.00004898694,0.0003354078,0.0002753458,0.00007211493,0.0009234087,0.003383519,0.0003027155,0.003479941,0.00003089014],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987257,0.002881749,0.0009099187,0.0007501674,0.000206042,0.003011655,0.002104418,0.0001995021,0.002679568],"genre_scores_gemma":[0.9855291,0.001647798,0.001750244,0.001345989,0.000204029,0.002434265,0.003130867,0.00005313124,0.003904459],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005784372,"threshold_uncertainty_score":0.01935065,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0865494763517485,"score_gpt":0.4815242672372223,"score_spread":0.3949747908854738,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}